Popular Articles

Mar 16, 2018
James Burt, Accord Healthcare’s EVP, Europe and MENA, outlines his optimistic vision for the UK and Europe post-Brexit and the challenges of retaining a company culture amid major growth.
Feb 12, 2018
Pharmaceutical Executive
The biotech sector has managed to elude the negative perceptions saddling traditional pharma these days. We examine the reasons why.
Feb 12, 2018
Pharmaceutical Executive
Lieutenant General (Ret) Rick Lynch, US Army, and Bob Jansen, CEO of Zensights, discuss the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader.
Feb 12, 2018
Pharmaceutical Executive
Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to its stakeholders—most importantly, patients and the wider public.
Feb 11, 2018
Jin Zhang reviews the current fortunes of the Chinese pharmaceutical companies.
Feb 11, 2018
Pharmaceutical Executive
In this Q&A, Richard Lajoie, the new head of Valeant Canada, shares his main priorities for the business, including growing its domestic manufacturing as a key cog globally.
Jan 26, 2018
Pharmaceutical Executive
In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.
Jan 12, 2018
Pharmaceutical Executive
Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer and the related broader issues such as pricing and value and new innovations in cancer science.
Aug 29, 2017
Pharmaceutical Executive
IFPMA's new Assistant Director General speaks about her mission to use the organization’s international reach to find real and practical solutions to the most pressing global healthcare challenges.
Aug 09, 2017
Pharmaceutical Executive
Pharm Exec’s 13th Annual Press Audit reveals a tonal undercurrent in sync with an industry unable to escape the glare of scrutiny.
native1_300x100
lorem ipsum